Gemzar Narrow Progression-Free Survival Benefit To Test Oncology Panel's Efficacy Bar
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Oncologic Drugs Advisory Committee will review Lilly's gemcitabine for treatment of advanced ovarian cancer March 13.
You may also be interested in...
Gemzar Ovarian Cancer Data Not Sufficient For Approval In Recurrent Disease, Committee Says
While FDA advisory committee accepts that Lilly’s Gemzar plus carboplatin may have had an effect on progression-free survival in ovarian cancer, poor study design and lack of overall survival benefit sink approval recommendation.
Gemzar Ovarian Cancer Data Not Sufficient For Approval In Recurrent Disease, Committee Says
While FDA advisory committee accepts that Lilly’s Gemzar plus carboplatin may have had an effect on progression-free survival in ovarian cancer, poor study design and lack of overall survival benefit sink approval recommendation.
Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says
The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.